Pharmaceuticals - Diversified

Spectrum Pharmaceuticals Inc Announces Additional Extension Of Tender Offer Period For Shares Of Allos Therapeutics, Inc.

Spectrum Pharmaceuticals Inc and Allos Therapeutics, Inc. announced that Spectrum has provided an additional extension of the offer period in connection with tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any...

Friday, 3 Aug 2012 07:05pm EDT

FDA Approves Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for Metastatic Colorectal Cancer-Reuters

Reuters reported that the U.S. Food and Drug Administration has approved Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for use in combination with a folinic acid, fluorouracil and irinotecan chemotherapy regimen to treat adults with colorectal cancer.

Friday, 3 Aug 2012 11:05am EDT

Glaxosmithkline Plc Completes Acquisition Of Human Genome Sciences

Glaxosmithkline Plc announced that it has completed its acquisition of Human Genome Sciences for USD3.6 billion on an equity basis, or approximately USD3 billion net of cash and debt. All outstanding shares of HGS were acquired for USD14.25 per share in cash. Pursuant to the terms of the merger...

Friday, 3 Aug 2012 02:00am EDT

Glenmark Pharmaceuticals Ltd Announces Demise of Chairman Emeritus

Glenmark Pharmaceuticals Ltd announced that Mr. Gracias Saldanha, Founder and Chairman Emeritus of the Company passed away on July 21, 2012.

Thursday, 2 Aug 2012 08:30am EDT

Valeant Pharmaceuticals International Inc Raises FY 2012 EPS Guidance; Reaffirms FY 2012 Revenue Guidance

Valeant Pharmaceuticals International Inc updated fiscal 2012 guidance and increased cash EPS to $4.55 to $4.75 (or $4.18 to $4.38 excluding one-time items) in fiscal 2012, up from prior guidance of $4.45 to $4.70, and maintained prior guidance of total revenue in the range of $3.4 to $3.6 billion...

Thursday, 2 Aug 2012 07:09am EDT

Teva Pharmaceutical Industries Ltd Declares Dividend; Reaffirms FY 2012 Guidance

Teva Pharmaceutical Industries Ltd announced that the Board of Directors, at its meeting on July 31, 2012, declared a cash dividend for the second quarter of 2012 of NIS1.00 (approximately $0.25 according to the rate of exchange on July 31, 2012) per share. The record date will be August 15, 2012,...

Thursday, 2 Aug 2012 07:05am EDT

Bristol-Myers Squibb Co Suspends Administration Of Study Drug In Clinical Trial Of Investigational NS5B Nucleotide For The Treatment Of Hepatitis C

Bristol-Myers Squibb Co announced that the Company has suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken to protect...

Wednesday, 1 Aug 2012 08:37pm EDT

BioMarin Pharmaceutical, Inc. Reaffirms FY 2012 Revenue Guidance; Lowers FY 2012 Earnings Guidance

BioMarin Pharmaceutical, Inc. announced that for fiscal 2012, it now expects total revenues in the range of $475 million to $510 million, GAAP Net (Loss) in the range of $(115) million to (105) million (prior guidance for fiscal 2012 GAAP Net (Loss) was in the range of $(92) million to $(82)...

Wednesday, 1 Aug 2012 04:00pm EDT

Albany Molecular Research, Inc. Issues Q3 2012 EPS Guidance In Line With Analysts' Estimates; Raises FY 2012 EPS Guidance

Albany Molecular Research, Inc. announced that for the third quarter of 2012, it expects adjusted earnings per diluted share to be $(0.04) to zero. For fiscal 2012, it is raising adjusted earnings per diluted share estimate to range from $0.10-$0.16. According to I/B/E/S Estimates, analysts were...

Wednesday, 1 Aug 2012 08:15am EDT

Hemispherx Biopharma, Inc. Files Complete Response With FDA Regarding Ampligen New Drug Application For Chronic Fatigue Syndrome

Hemispherx Biopharma, Inc. announced that the U.S. Food and Drug Administration complete response to the FDA's November 25, 2009 Complete Response Letter (CRL) in support of Ampligen's New Drug Application for Chronic Fatigue Syndrome (CFS). At present, no drug has received FDA approval to treat...

Wednesday, 1 Aug 2012 08:01am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.